JNJ-6143, a First-in-Class Oral AR-Targeted RIPTAC, in Heavily Pretreated #mCRPC: Phase 1 Safety and Efficacy. Presented by @BGarmezy @SarahCannonDocs. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4epG5Xi #ProstateCancer @myESMO